The Risks and Opportunities of Homeostatic Repopulation

稳态增殖的风险和机遇

基本信息

  • 批准号:
    9751206
  • 负责人:
  • 金额:
    $ 243.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-15 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT – Overall Thousands of patients benefit each year from the lifesaving impacts of organ transplantation, but this benefit is hampered by the requirement of preventing rejection of the donor graft. Establishing immunologic tolerance in organ transplant recipients using life-long immunosuppressive therapy, in particular, the lymphocyte depletion immunosuppression strategy has been a critical component of all successful approaches. Following lymphocyte depletion, immune cells proliferate to fill the newly created gap in the immune repertoire, a process referred to as homeostatic repopulation. During this process the immune microenvironment critically influences the ensuing immunologic repertoire and can detour the response to allogeneic donor tissue either toward rejection or tolerance. We propose that the post-depletional fate of lymphocytes depends on its differentiation state, its exposure to antigen, and the effect of exogenous factors driving or inhibiting its growth. Within this context, we advance a generalizable framework for repopulation: recollective homeostasis, positing that the lymphocyte repertoire at any given time is determined by an ongoing process of memory acquisition and deletion. Importantly, depletion accelerates turnover, creating an intense period of opportunity during which we propose this process can be manipulated, exploiting relative differences in cell susceptibility to create, over time, a state of sustained allospecific hypo-responsiveness. This proposal seeks to capitalize on this window of opportunity to reshape the immune repertoire towards tolerance through the work of two interrelated projects investigating specific repopulation events supported by an administrative core and a scientific core for immune profiling. Project 1 will focus on depletional T lymphocyte repopulation, while Project 2 will focus on B lymphocyte/plasma cell/antibody modulation. These projects are scientifically distinct but are interactive in methodologies and mechanisms. Specifically, both projects will employ our major histocompatibility complex (MHC)-defined, nonhuman primate (NHP) renal transplantation model that provides rigorous translational evaluation of potential novel tolerance induction strategies. Homeostatic repopulation is a central theme in our work that serves to generalize our approach beyond tolerance protocols, to broader immunosuppressant- and viral-induced lymphopenic states. This proposal will also improve upon our understanding of the role of costimulation blockade and the drug belatacept in tolerance induction; their ability to enhance the specificity and tolerability of anti-rejection therapy and to downregulate alloantibody has been a longstanding focus of our research. Our proposed studies will build on two decades of collaborative experience investigating both depletion and costimulation blockade in NHPs. The knowledge gained from these studies will further our understanding of tolerance mechanisms in NHPs and humans, extend our understanding of T and B cell biology, and deepen our understanding of transplant immunosuppression.
摘要-总体

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stuart Johnston Knechtle其他文献

Stuart Johnston Knechtle的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stuart Johnston Knechtle', 18)}}的其他基金

Targeting the B Cell Response to Treat Antibody-Mediated Rejection
靶向 B 细胞反应来治疗抗体介导的排斥反应
  • 批准号:
    10636822
  • 财政年份:
    2021
  • 资助金额:
    $ 243.43万
  • 项目类别:
Targeting the B Cell Response to Treat Antibody-Mediated Rejection
靶向 B 细胞反应来治疗抗体介导的排斥反应
  • 批准号:
    10472725
  • 财政年份:
    2021
  • 资助金额:
    $ 243.43万
  • 项目类别:
Targeting the B Cell Response to Treat Antibody-Mediated Rejection
靶向 B 细胞反应来治疗抗体介导的排斥反应
  • 批准号:
    10283031
  • 财政年份:
    2021
  • 资助金额:
    $ 243.43万
  • 项目类别:
The Risks and Opportunities of Homeostatic Repopulation
稳态增殖的风险和机遇
  • 批准号:
    9980776
  • 财政年份:
    2017
  • 资助金额:
    $ 243.43万
  • 项目类别:
Depletion, Repopulation and Tolerance in Sensitized Recipients
致敏受体的消耗、再生和耐受性
  • 批准号:
    10649946
  • 财政年份:
    2017
  • 资助金额:
    $ 243.43万
  • 项目类别:
The Risks and Opportunities of Homeostatic Repopulation
稳态增殖的风险和机遇
  • 批准号:
    10622054
  • 财政年份:
    2017
  • 资助金额:
    $ 243.43万
  • 项目类别:
Depletion, Repopulation and Tolerance in Sensitized Recipients
致敏受体的消耗、再生和耐受性
  • 批准号:
    9980792
  • 财政年份:
    2017
  • 资助金额:
    $ 243.43万
  • 项目类别:
Depletion, Repopulation and Tolerance in Sensitized Recipients
致敏受体的消耗、再生和耐受性
  • 批准号:
    10214496
  • 财政年份:
    2017
  • 资助金额:
    $ 243.43万
  • 项目类别:
The Risks and Opportunities of Homeostatic Repopulation
稳态增殖的风险和机遇
  • 批准号:
    10518424
  • 财政年份:
    2017
  • 资助金额:
    $ 243.43万
  • 项目类别:
The Risks and Opportunities of Homeostatic Repopulation
稳态增殖的风险和机遇
  • 批准号:
    10214492
  • 财政年份:
    2017
  • 资助金额:
    $ 243.43万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 243.43万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 243.43万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 243.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 243.43万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 243.43万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 243.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 243.43万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 243.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 243.43万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 243.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了